Enzalutamide and Venetoclax: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong or moderate CYP3A induction can reduce venetoclax exposure.
Clinical significance and safety
Avoid Enzalutamide with Venetoclax where possible because enzyme induction can lower venetoclax exposure and reduce treatment effectiveness. The venetoclax product information recommends an alternative with less CYP3A-inducing activity. The oncology team should choose the alternative and manage any transition; do not change either medicine yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.